Timeline Details of BRACELET-1 Presentation on June 3, 2023 Below is the breakdown of the six presentations during this 1.5 hour symposium. Six presentions of 12 minutes each will be made, including a presentation re. BRACELET-1 by Amy Sanders Clark of the University of Pennsylvania. The final 18 minutes of the symposium will be a pannel discussion.
Clinical Science Symposium S406
The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: Harnessing the Breast Cancer Immune Response
Primary Track: Breast Cancer
Presenters summarize research findings, while discussants place the abstracts in the appropriate context with a focus on how the findings apply to clinical practice. Abstracts in these sessions may span disease sites or disciplines, but they are unified by their focus on a key scientific topic.
Presentations
-
11:15 AM PDT
Characterization of the immune microenvironment in matched primary and metastatic breast cancer lesions from the AURORA study: BIG 14-01.
Presenter: Florentine Hilbers, PhD | Department of Molecular Pathology, Netherlands Cancer Institute
-
11:27 AM PDT
Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).
Presenter: Daniel G. Stover, MD | Ohio State University Comprehensive Cancer Center
-
11:39 AM PDT
Tumor-Infiltrating Lymphocytes: Important unTIL They’re Not
Discussant: Kim Blenman, PhD, MS | Yale University
-
11:51 AM PDT
RNA expression levels from peripheral immune cells, a minimally invasive liquid biopsy source to predict response to therapy, survival and immune-related adverse events in patients with triple negative breast cancer enrolled in the GeparNuevo trial.
Presenter: Hanna Hbner, PhD | Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universitt Erlangen-Nrnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN)
-
12:03 PM PDT
BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab.
Presenter: Amy Sanders Clark, MD, MSCE | University of Pennsylvania
-
12:15 PM PDT
Immune Awakening: Dynamic Immune Cell Monitoring and Immunotherapy
Discussant: Sherene Loi, MD | Peter MacCallum Cancer Centre
-
12:27 PM PDT
Panel Question and Answer
Panel Speaker: Panel Discussion | ASCO